NyQuil

NyQuil is a Vicks brand of over-the-counter nighttime cold and flu medicines owned and marketed by Procter & Gamble. The brand was first introduced in the United States in 1966 and became one of the best-known products in the nighttime cough-and-cold category. Its central proposition is to combine relief for several common cold or flu symptoms in one product while supporting nighttime rest. Depending on the formulation and market, NyQuil products may address coughing, runny nose, sneezing, minor aches, fever, sore throat discomfort and nasal congestion. The brand is built around sedating nighttime formulations. Traditional NyQuil products have used doxylamine succinate, a first-generation antihistamine that can cause drowsiness, together with other active ingredients such as acetaminophen for pain and fever relief and dextromethorphan for cough suppression. Some formulations have also included an oral decongestant, historically pseudoephedrine and, in later formulations, phenylephrine. Because formulations vary by product and country, the label of the specific package is the authoritative source for ingredients, dosage and warnings. NyQuil’s positioning historically differentiated it from single-symptom medicines by presenting a broad combination of relief in a single liquid dose. Vicks has described the product as an early multi-symptom nighttime cough and cold medicine. The brand’s familiar green packaging, liquid format, dosing cup and nighttime orientation helped establish a distinctive identity in American medicine cabinets. The product later expanded into LiquiCaps and other capsule formats, making the brand more convenient for consumers who preferred a non-liquid dose. NyQuil is closely associated with DayQuil, its daytime counterpart. DayQuil was designed to provide comparable cold and flu symptom relief without the sedating antihistamine used in nighttime products. Together, the two brands form a day-and-night regimen within the Vicks portfolio, with NyQuil focused on nighttime relief and sleep and DayQuil focused on daytime use. The NyQuil line has included standard Cold & Flu or Cold/Flu multisymptom products, NyQuil SEVERE, NyQuil D, NyQuil Cough and NyQuil Sinus variants. Availability and formulas have changed over time. In the United States, regulatory changes affecting pseudoephedrine contributed to reformulation of some products in 2006, while NyQuil D continued to use pseudoephedrine in certain formulations. More recently, oral phenylephrine became the subject of FDA scrutiny after an advisory committee concluded in 2023 that available scientific data did not support its effectiveness at the recommended dose as a nasal decongestant. That regulatory development has relevance to some NyQuil products containing oral phenylephrine, although the FDA’s advisory conclusion did not itself immediately constitute a final product withdrawal. NyQuil has also become a prominent advertising brand. Its long-form description of nighttime relief became a memorable piece of American consumer-health advertising, while later campaigns used humor, family situations, sports figures and product extensions such as honey-flavored liquid medicines. The brand remains active as part of P&G’s global personal healthcare portfolio and continues to compete in the over-the-counter cough, cold and flu market.

NyQuil emerged from the Vicks cough-and-cold business in the United States during the expansion of combination over-the-counter medicines. It was first marketed in 1966, when consumers commonly relied on separate products for cough, congestion, fever, aches and other cold symptoms. NyQuil’s distinctive contribution was to assemble several forms of nighttime symptom relief into one branded product. The concept made the medicine convenient while also establishing a clear use occasion: taking the product before sleep when illness made rest difficult. The brand’s traditional formulation combined a sedating antihistamine with other symptom-relief ingredients. Doxylamine succinate served as the nighttime antihistamine and sedating component, while acetaminophen and dextromethorphan addressed pain or fever and cough respectively in relevant formulations. The precise composition changed across products and over time, and consumers were directed to use the label for the formulation in their market. During the 1970s, Vicks developed the connection between NyQuil and nighttime recovery more explicitly. Vicks’ own historical account identifies 1979 as the period when the product’s famous descriptive advertising line was coined. Rather than relying only on a short brand slogan, the communication listed a series of symptoms—sniffling, sneezing, coughing, aching, stuffy head and fever—and concluded with the promise that the medicine allowed the user to rest. This helped make the product’s functional breadth part of its cultural identity. NyQuil’s daytime counterpart developed alongside the nighttime product. Vicks introduced a daytime product under the DayCare name in the 1970s and later used the DayQuil name. DayQuil removed the sedating antihistamine associated with nighttime use, allowing Vicks to organize its cold-and-flu portfolio around a day-versus-night routine. The pairing strengthened NyQuil’s role as the nighttime half of a broader regimen rather than an isolated medicine. The brand later expanded beyond its original liquid presentation. In the early 1990s, Vicks introduced LiquiCaps, liquid-filled capsules that offered an alternative to syrup. The capsule format supported convenience and portability while preserving the recognizable NyQuil proposition. Additional line extensions included stronger multisymptom products, cough-focused variants, sinus products and formulations with different decongestants. Regulation affected the product architecture in the 2000s. The Combat Methamphetamine Epidemic Act of 2005, implemented in 2006, imposed restrictions and purchase-record requirements on pseudoephedrine-containing medicines in the United States. Vicks reformulated some NyQuil products, replacing pseudoephedrine with phenylephrine in certain products such as NyQuil Sinus, while retaining pseudoephedrine in NyQuil D in relevant markets. This change illustrated how external regulation can alter an established consumer-health formula without eliminating the brand. Ownership of the Vicks business also changed over NyQuil’s history. Vicks was historically operated by Richardson-Vicks and related corporate entities before Procter & Gamble acquired Richardson-Vicks in 1985. NyQuil subsequently became part of P&G’s global personal healthcare portfolio. The brand continued to be marketed alongside Vicks products such as DayQuil, Sinex and VapoRub, with local product availability and formulation varying by country. In the 2010s and 2020s, NyQuil advertising continued to use humor, family situations, sports associations and celebrity-led or personality-led creative executions. Campaigns presented the product as a practical answer to the disruption caused by being sick at night, while newer product work emphasized flavor and formats such as honey liquids. P&G described NyQuil and DayQuil Honey as examples of product and communication innovation in its Vicks portfolio. The brand has also faced public scrutiny. In 2007, an advertising self-regulatory proceeding recommended modifications to certain NyQuil claims. In 2022, the FDA warned consumers against heating or cooking food with NyQuil after a social-media-associated practice received attention. In 2023, an FDA advisory committee concluded that available scientific data did not support the effectiveness of oral phenylephrine at the recommended dose as a nasal decongestant. That issue was relevant to some NyQuil formulations containing the ingredient, but the advisory conclusion was not an immediate final ban or recall. NyQuil remains an active and internationally recognized nighttime cough, cold and flu brand. Its enduring identity rests on the combination of broad symptom coverage, a sedating nighttime formulation, distinctive Vicks branding, and decades of advertising that made the act of taking cold medicine before bed a familiar consumer-health ritual.

• 2023

  FDA advisory committee questions oral phenylephrine effectiveness

  [7]FDA clarification on oral phenylephrinefda.gov

  An FDA advisory committee concluded that available data did not support oral phenylephrine’s effectiveness at the recommended dose as a nasal decongestant.

• 2022

  FDA issues warning about cooking with NyQuil

  [12]FDA issues warning about cooking with NyQuilfda.gov

  The FDA warned against heating or cooking food with NyQuil after the practice circulated in social-media discussions.

• 2007

  Advertising claims reviewed by NAD

  [8]National Advertising Division decision involving NyQuil advertisingbbbprograms.org

  The National Advertising Division recommended that P&G modify certain advertising claims for NyQuil Multi-Symptom Cold/Flu Relief.

• 2006

  Some decongestant formulations changed

  [1]NyQuilen.wikipedia.org

  Following U.S. pseudoephedrine controls, Vicks reformulated some NyQuil products by replacing pseudoephedrine with phenylephrine.

• 1991

  NyQuil LiquiCaps introduced

  [11]NyQuil LiquiCaps introducedvicks.com.au

  Vicks introduced liquid-filled capsule technology for NyQuil in the United States, expanding the brand beyond syrup.

• 1985

  Richardson-Vicks acquired by Procter & Gamble

  [5]Vicksen.wikipedia.org

  The Vicks business, including NyQuil, became part of Procter & Gamble’s brand portfolio.

• 1979

  Nighttime symptom-relief advertising identity established

  [2]Power You Trust: NyQuil Creation Storyvicks.com

  Vicks identifies 1979 as the year its famous descriptive nighttime cold-medicine advertising line was coined.

• 1966

  NyQuil introduced in the United States

  [2]Power You Trust: NyQuil Creation Storyvicks.com

  Vicks first marketed NyQuil as a nighttime, multi-symptom cough and cold medicine.

A trusted, broadly distributed nighttime over-the-counter medicine offering multi-symptom cold and flu relief in liquid and capsule formats, with drowsiness and nighttime rest forming important elements of the brand proposition.

• Nighttime multisymptom cold and flu medicine · 1966

  NyQuil Cold & Flu Nighttime Relief

  The core NyQuil offering is available in liquid and capsule formats. Depending on the formulation, it combines a sedating antihistamine such as doxylamine succinate with a cough suppressant such as dextromethorphan and a pain or fever reducer such as acetaminophen. The product is intended for nighttime symptom relief and may cause drowsiness. Exact active ingredients and strengths vary by package and market.

• Maximum-strength nighttime multisymptom medicine

  NyQuil SEVERE Cold & Flu

  NyQuil SEVERE extends the standard nighttime product proposition to a broader combination intended for several cold and flu symptoms. U.S. formulations have included acetaminophen, dextromethorphan, doxylamine succinate and an oral decongestant such as phenylephrine. Products are sold in liquid and capsule or caplet formats, with the exact formula subject to change.

• Nighttime cold and flu medicine with pseudoephedrine

  NyQuil D

  NyQuil D is a decongestant-oriented variant that has used pseudoephedrine in relevant formulations. In the United States, pseudoephedrine products are subject to pharmacy-counter controls and purchase restrictions. The formulation also combines nighttime antihistamine and cough, pain or fever relief ingredients according to the product label.

• Nighttime cough medicine

  NyQuil Cough

  NyQuil Cough is a more focused nighttime product intended primarily for cough relief. The formulation described in reference material contains dextromethorphan as a cough suppressant and doxylamine succinate as the sedating antihistamine. Unlike standard multisymptom products, it does not center on a pain or fever reducer.

• Nighttime sinus and congestion medicine

  NyQuil Sinus

  NyQuil Sinus was offered as a LiquiCaps product combining nighttime antihistamine effects with pain or fever relief and a nasal decongestant. Its U.S. formula was changed in 2006 from pseudoephedrine to phenylephrine following regulatory restrictions on pseudoephedrine sales. Product composition and availability may differ by market.

• Honey-flavored nighttime cold medicine

  NyQuil Honey

  NyQuil Honey is part of a newer product-extension strategy emphasizing flavor and consumer experience. P&G has highlighted NyQuil and DayQuil Honey as innovations within the Vicks cough, cold and flu portfolio. The products are marketed as nighttime or daytime medicines depending on the specific NyQuil or DayQuil formulation.

• 2023

  Oral phenylephrine effectiveness controversy

  An FDA advisory committee concluded that available scientific data did not support oral phenylephrine’s effectiveness at the recommended dose as a nasal decongestant. Because some NyQuil formulations have contained oral phenylephrine, the conclusion became relevant to the brand and to the wider OTC cold-medicine category. The FDA stated that the advisory recommendation was not itself a final agency decision.

  Source

• 2022

  NyQuil cooking social-media controversy

  A social-media-associated practice involving cooking or heating chicken with NyQuil led the FDA to warn consumers not to heat or cook food with the medicine. The FDA cited risks from concentrating the ingredients and inhaling vapors. The practice was not an intended use of the product.

  Source

• 2007

  Advertising claims challenge before the National Advertising Division

  The National Advertising Division reviewed a challenge involving P&G advertising for NyQuil Multi-Symptom Cold/Flu Relief and recommended modifications to certain claims. The matter concerned advertising substantiation and presentation.

  Source

Read more

• 2023NyQuil and DayQuil Honey communication

  United States · International Vicks markets

  P&G highlighted NyQuil and DayQuil Honey in corporate brand communication, emphasizing flavor, product innovation and the day-and-night Vicks regimen.

  Outcome. The products were presented as examples of Vicks innovation and communication intended to strengthen the cough, cold and flu portfolio.

  Source
• 2016Moms Don't Take Sick Days

  United States

  A NyQuil SEVERE television spot used a humorous family scenario in which a sick mother seeks a break but ultimately uses NyQuil SEVERE and sleeps through her illness.

  Outcome. The campaign reinforced the idea of NyQuil SEVERE as nighttime relief for consumers managing cold or flu symptoms during demanding family routines.

  Source
• 2012Football-season mobile advertising

  United States

  Vicks used mobile advertising built around an interactive football-themed game to promote DayQuil and NyQuil in Yahoo fantasy-football environments during the cold-and-flu season.

  Outcome. The campaign connected seasonal illness messaging with football engagement and promoted both the daytime and nighttime products.

  Source
• 1979Nighttime symptom-relief positioning

  United States

  Vicks established the long-form advertising language that linked NyQuil with relief from multiple cold symptoms and the ability to rest at night.

  Outcome. The message became one of the brand’s most recognizable pieces of positioning and helped distinguish NyQuil from single-symptom medicines.

  Source

• 2023

  Honey product extensionProduct launch

  Background

  P&G’s Vicks strategy emphasized product superiority, consumer experience and new formats or flavor profiles in the cough, cold and flu category.

  Action taken

  P&G promoted NyQuil Honey and its DayQuil counterpart as product innovations within the Vicks portfolio.

  Aftermath

  The extension added a flavor-led proposition to the established day-and-night Vicks regimen.

  Source

• 2023

  Continued investment in Vicks brand superiorityStrategy

  Background

  P&G described Vicks as a major global OTC cough, cold and flu brand and emphasized innovation, communication and product experience as growth drivers.

  Action taken

  P&G continued to support Vicks through product innovation and communication, including NyQuil and DayQuil Honey.

  Aftermath

  NyQuil remained positioned as a core nighttime pillar of P&G’s personal healthcare portfolio.

  Source

• 2006

  Reformulation following pseudoephedrine restrictionsGeneration change

  Background

  U.S. legislation placed additional controls on pseudoephedrine-containing medicines because pseudoephedrine can be used in illicit methamphetamine production.

  Action taken

  Vicks replaced pseudoephedrine with phenylephrine in some NyQuil products, including NyQuil Sinus, while NyQuil D remained associated with pseudoephedrine in relevant formulations.

  Aftermath

  The change altered the decongestant composition of parts of the NyQuil range and made product selection more dependent on local pharmacy rules and package labeling.

  Source

• 1991

  Expansion into LiquiCapsProduct launch

  Background

  NyQuil had been strongly associated with liquid syrup, while consumers also sought more portable and convenient dosage forms.

  Action taken

  Vicks introduced NyQuil LiquiCaps, a liquid-filled capsule format.

  Aftermath

  The capsule format broadened the brand’s usage occasions and gave consumers an alternative to syrup.

  Source

• 2023

  P&G highlights NyQuil and DayQuil Honey innovation[6]Procter & Gamble 2023 Annual Report: Superiority That Wins with Consumersus.pg.com

  Product launch · Campaign · Other

  Procter & Gamble identified NyQuil and DayQuil Honey as examples of innovation in its Vicks cough, cold and flu portfolio, emphasizing product experience, flavor and communication as part of the brand’s growth strategy.

1. 1NyQuilen.wikipedia.org
2. 2Power You Trust: NyQuil Creation Storyvicks.com
3. 3NyQuil product rangevicks.com
4. 4NyQuil Cold & Flu Nighttime Relief Liquidvicks.com
5. 5Vicksen.wikipedia.org
6. 6Procter & Gamble 2023 Annual Report: Superiority That Wins with Consumersus.pg.com
7. 7FDA clarification on oral phenylephrinefda.gov
8. 8National Advertising Division decision involving NyQuil advertisingbbbprograms.org
9. 9NyQuil and DayQuil mobile advertising campaignmarketingdive.com
10. 10NyQuil SEVERE: Moms Don't Take Sick Daysispot.tv
11. 11NyQuil LiquiCaps introducedvicks.com.au
12. 12FDA issues warning about cooking with NyQuilfda.gov
13. 13FDA警告消费者不要用NyQuil煮鸡肉fda.gov